神经分泌生物科学 NBIX 深 沪
已收盘 10-02 16:00:00 美东时间
143.18
+2.470
+1.76%
华盛通- 最 高144.56
- 今 开141.41
- 成交量 164.83万股
- 最 低 140.36
- 昨 收 140.71
- 总市值 145.54亿
- 52周最高 186.12
- 市盈率 静 30.66
- 换手率 1.62%
- 52周最低 122.1375
- 委 比 -81.60%
- 总股本 1.02亿
- 历史最高 186.12
- 量 比 1.03
- 振 幅 2.98%
- 历史最低 5.42
- 每 手 1
- 风险率 14.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Unicycive Therapeutics Appoints Meredith Manning to Board of Directors
Unicycive Therapeutics announced the appointment of Meredith Manning, M.B.A., to its Board of Directors. With over 25 years of global biopharmaceutical experience, Manning brings expertise in commercialization and product launches. She previously led the U.S. launch of VYKAT™ XR at Soleno Therapeutics and contributed to the FDA approval of BESREMi® at PharmaEssentia. Manning will serve on the Audit, Compensation, and Nominating and Corporate Gove...
10-01 11:05
美股大行评级 | 潜在涨幅11184.05%！如瑞迪博士获花旗上调目标价至1450美元，维持"买入"评级
今日重点评级关注：花旗：上调如瑞迪博士"买入"评级，目标价从1040美元升至1450美元；加拿大帝国商业银行：维持Inventiva"买入"评级，目标价从20美元升至21美元
09-30 08:33
UBS Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $214
UBS analyst Ashwani Verma maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and lowers the price target from $231 to $214.
09-30 03:04
Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer
SAN DIEGO, Sept. 28, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Eiry W. Roberts, M.D., who previously served as Neurocrine's Chief Medical Officer ...
09-29 04:05
Bernstein Remains a Buy on Neurocrine (NBIX)
In a report released yesterday, Jeffrey Walch from Bernstein maintained a Buy r...
09-26 20:16
美股大行评级 | Adobe绩后获多家大行齐升目标价！最高看多至270美元；甲骨文绩后现多空分歧
今日重点评级关注：Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从10美元升至10.5美元；摩根士丹利：维持Aurora Innovation"超配"评级，目标价从14美元升至18美元
09-14 16:05
Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $183
Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-Weight and raises the price target from $182 to $183.
09-12 01:44
美股大行评级 | 多家大行齐上调Robinhood目标价！最高看至150美元；安进股价大跌后评级遭下调
今日重点评级关注：Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.3美元升至8.45美元；摩根大通：维持Vera Therapeutics"超配"评级，目标价从76美元升至83美元
09-09 15:36
美股大行评级 | 大行齐上调AI应用股目标价！Adobe、CRWD等获看好，慧与科技绩后现多空分歧
今日重点评级关注：BTIG：维持Climb Bio"买入"评级，目标价从20美元升至32美元；巴克莱：维持Alpha Tau Medical"超配"评级，目标价从17美元升至30美元
09-04 12:30
Citigroup Maintains Buy on Neurocrine Biosciences, Raises Price Target to $253
Citigroup analyst Yigal Nochomovitz maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $249 to $253.
09-04 00:28
